Literature DB >> 20112424

5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice.

Marcos Martínez-Clemente1, Natàlia Ferré, Ana González-Périz, Marta López-Parra, Raquel Horrillo, Esther Titos, Eva Morán-Salvador, Rosa Miquel, Vicente Arroyo, Colin D Funk, Joan Clària.   

Abstract

UNLABELLED: The actual risk factors that drive hepatic inflammation during the transition from steatosis to steatohepatitis are unknown. We recently demonstrated that hyperlipidemia-prone apolipoprotein E-deficient (ApoE(-/-)) mice exhibit hepatic steatosis and increased susceptibility to hepatic inflammation and advanced fibrosis. Because the proinflammatory 5-lipoxygenase (5-LO) pathway was found to be up-regulated in these mice and given that 5-LO deficiency confers cardiovascular protection to ApoE(-/-) mice, we determined the extent to which the absence of 5-LO would alter liver injury in these mice. Compared with ApoE(-/-) mice, which showed expected hepatic steatosis and inflammation, ApoE/5-LO double-deficient (ApoE(-/-)/5-LO(-/-)) mice exhibited reduced hepatic inflammation, macrophage infiltration, tumor necrosis factor alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and interleukin (IL)-18 expression, caspase-3 and nuclear factor-kappaB (NF-kappaB) activities, and serum alanine aminotransferase levels in the absence of changes in hepatic steatosis. The lack of 5-LO produced a remarkable insulin-sensitizing effect in the adipose tissue because peroxisome proliferator-activated receptor gamma, insulin receptor substrate-1, and adiponectin were up-regulated, whereas c-Jun amino-terminal kinase phosphorylation and MCP-1 and IL-6 expression were down-regulated. On the other hand, hepatocytes isolated from ApoE(-/-)/5-LO(-/-) mice were more resistant to TNF-alpha-induced apoptosis. The 5-LO products leukotriene (LT) B(4), LTD(4), and 5-HETE consistently triggered TNF-alpha-induced apoptosis and compromised hepatocyte survival by suppressing NF-kappaB activity in the presence of actinomycin D. Moreover, ApoE(-/-)/5-LO(-/-) mice were protected against sustained high-fat diet (HFD)-induced liver injury and hepatic inflammation, macrophage infiltration and insulin resistance were significantly milder than those of ApoE(-/-) mice. Finally, pharmacological inhibition of 5-LO significantly reduced hepatic inflammatory infiltrate in the HFD and ob/ob models of fatty liver disease.
CONCLUSION: These combined data indicate that hyperlipidemic mice lacking 5-LO are protected against hepatic inflammatory injury, suggesting that 5-LO is involved in mounting hepatic inflammation in metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112424     DOI: 10.1002/hep.23463

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Ethanol promotes chemically induced oral cancer in mice through activation of the 5-lipoxygenase pathway of arachidonic acid metabolism.

Authors:  Yizhu Guo; Xin Wang; Xinyan Zhang; Zheng Sun; Xiaoxin Chen
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

Review 2.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

3.  A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice.

Authors:  Indrani Sinha-Hikim; Amiya P Sinha-Hikim; Ruoqing Shen; Hyun Ju Kim; H Kim; Samuel W French; Nosratola D Vaziri; Nosratola D Vaziri; Albert C Crum; Albert Crum; Tripathi B Rajavashisth; Keith C Norris
Journal:  Exp Mol Pathol       Date:  2011-05-03       Impact factor: 3.362

4.  Circulating LTD4 in patients with hepatocellular carcinoma.

Authors:  Yan Zhou; Dongmei Guo; Huiyu Li; Shenghua Jie
Journal:  Tumour Biol       Date:  2010-09-06

Review 5.  Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.

Authors:  Matthew Spite; Joan Clària; Charles N Serhan
Journal:  Cell Metab       Date:  2013-11-14       Impact factor: 27.287

Review 6.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

Review 7.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus.

Authors:  Weiling Leng; Mingxia Wu; Hang Pan; Xiaotian Lei; Liu Chen; Qinan Wu; Xinshou Ouyang; Ziwen Liang
Journal:  Ann Transl Med       Date:  2019-09

9.  Resolution of inflammation in obesity-induced liver disease.

Authors:  Bibiana Rius; Cristina López-Vicario; Ana González-Périz; Eva Morán-Salvador; Verónica García-Alonso; Joan Clária; Esther Titos
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

10.  Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice.

Authors:  Isabelle Mothe-Satney; Chantal Filloux; Hind Amghar; Catherine Pons; Virginie Bourlier; Jean Galitzky; Paul A Grimaldi; Chloé C Féral; Anne Bouloumié; Emmanuel Van Obberghen; Jaap G Neels
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.